姓名：周四元
性別：男
職稱：教授
學(xué)院：藥學(xué)系
研究方向：靶向遞藥系統(tǒng)與藥物代謝動力學(xué)研究

周四元，男， 2000年獲得第四軍醫(yī)大學(xué)藥理學(xué)專業(yè)博士學(xué)位, 2007-2009在美國康涅狄格州大學(xué)從事新藥篩選研究?，F(xiàn)任第四軍醫(yī)大學(xué)藥劑學(xué)教研室主任，教授，藥劑學(xué)專業(yè)碩士研究生導(dǎo)師，陜西省藥理學(xué)會常務(wù)理事，副秘書長，國家藥品價格評審專家。長期從事靶向遞藥系統(tǒng)與藥物代謝動力學(xué)研究，發(fā)表論文90余篇，其中SCI收錄論文18篇，獲得國家發(fā)明專利3項。2007年獲陜西省科技進步一等獎1項（第三）。在靶向遞藥系統(tǒng)研究方面，2005年獲國家科技部藥物制劑關(guān)鍵技術(shù)研究專項經(jīng)費支持，針對抗腫瘤化療藥物在臨床應(yīng)用過程中存在的問題，建立了大分子靶向藥物研究技術(shù)平臺，制備腫瘤靶向遞藥系統(tǒng)，通過藥效學(xué)及藥代動力學(xué)評價，可望篩選出腫瘤靶向性好、療效確切的遞藥系統(tǒng)。藥物代謝動力學(xué)研究2003年獲得國家科技部創(chuàng)新藥物臨床前藥物代謝動力學(xué)關(guān)鍵技術(shù)平臺建設(shè)專項經(jīng)費支持，建立了肝微粒體、Caco-2細(xì)胞、HepG2細(xì)胞、原位小腸、肝臟灌流等藥物吸收代謝研究模型，以及生物介質(zhì)中氨氯地平、白藜蘆醇苷等近30種藥物/代謝產(chǎn)物的HPLC以及LC/MS/MS檢測方法。藥物代謝動力學(xué)研究主要開展以下三個方面工作：（1）藥物吸收代謝篩選，（2）天然藥物代謝轉(zhuǎn)運機制研究，（3）新藥臨床前藥代動力學(xué)研究。

代表論文
1. Liu RW, Teng ZH, Yuan CJ, Huan ML, Liu XY, Zhou SY*. Liquid chromatography/positive-ion electrospray tandem mass spectrometry assay for nisoldipine in human plasma and its application to a pharmacokinetic study. Journal of Liquid Chromatography & Related Technologies.2011, 34(16): 1800-1810.
2. Zhang WD, Wang XJ, Zhou SY*, Gu Y, Wang R, Zhang TL, Gan HQ. Determination of free and glucuronidated kaempferol in rat plasma by LC-MS/MS: application to pharmacokinetic study.J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(23):2137-40.
3. Zhou SY, Mamdani M, Qanud K, Shen JB, Pappano AJ, Kumar ST, Jacobson KA, Hintze T, Recchia F, Liang B. Treatment of heart failure by a methanocarba derivative of adenosine monophosphate: implication for a role of cardiac P2X purinergic receptors. J. Pharmacol. Exp. Ther. 2010,333(3):920-8.
4. Kumar TS, Zhou SY, Joshi BV, Balasubramanian R, Yang T, Liang BT, Jacobson KA. Structure-activity relationship of (N)-methanocarba phosphonate analogues of 5'-AMP as cardioprotective agents acting through a cardiac P2X receptor. J.Med.Chem. 2010, 53(6):2562-76.
5. Zhang BL, He W, Shi X, Huan ML, Huang QJ, Zhou SY*. Synthesis and biological activity of the calcium modulator (R) and (S)-3-methyl 5-pentyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4- dihydropyridine-3,5- dicarboxylate. Bioorg. Med. Chem. Lett. 2010, 20(3):805-8.
6. Liu XY, Teng ZH, Zhang Y, Huan ML, Zhou SY. High performance liquid chromatography-tandem mass spectrometric determination of resveratrol and its metabolites in rat tissues. Analytical Letters. 2010,43(4): 557–569.
7. Zhou S, Yang R, Teng Z, Zhang B, Hu Y, Yang Z, Huan M, Zhang X, Mei Q. Dose-dependent absorption and metabolism of trans-polydatin in rats. J.Agric.Food Chem. 2009, 57(11):4572 -4579.
8. Huan ML, Zhou SY, Mei QB.Conjugation with α-linolenic acid improves cancer cell uptake and cytotoxicity of Doxorubicin. Bioorg.Med.Chem.Lett. 2009, 19(9): 2579-2584.
9.Zhou S, Zhang B, Liu X, Teng Z, Huan M, Yang T, Yang Z, Jia M, Mei Q. A new natural angelica polysaccharide based colon-specific drug delivery system. Journal of Pharmaceutical Science. 2009, 98(12):4756-68.
10.Zhou S, Hu Y, Zhang B, Teng Z, Gan H, Yang Z, Wang Q, Huan M, Mei Q. Dose-dependent absorption, metabolism, and excretion of genistein in rats. J.Agric.Food Chem. 2008, 56(18):8354-9.
11.Sonin D, Zhou SY, Cronin C, Sonina T, Wu J, Jacobson KA, Pappano AJ, Liang BT. Role of P2X purinergic receptors in the rescue of ischemic heart failure. Am J Physiol Heart Circ Physiol. 2008, 295(3):H1191-7.
12.Yang ZF, Zhou SY (co-first author), Yang TH, Liu XY, Mei QB. Pharmacokinetics of the analogs at C3 and C5 of m-nifedipine in beagle dogs. Biopharmaceutics and drug disposition. 2008, 29:485-494.
13.Teng ZH, Zhou SY (co-first author), Yang RT, Liu XY, Liu RW, Yang X, Zhang BL, Yang JY, Cao DY, Mei QB. Quantitation assay for absorption and first-pass metabolism of emodin in isolated rat small intestine using liquid chromatography-tandem mass spectrometry. Biol. Pharm. Bull. 2007, 30(9):1628-1633.
14.Teng ZH, Zhou SY, Ran YH, Liu XY, Liu RW, Yang X, Yuan CJ, Mei QB. Cellular absorption of anthraquinones emodin and chrysophanol in human intestinal Caco-2 cells. Biosci. Biotechnol. Biochem. 2007, 71(7):1636-1643.

如果發(fā)現(xiàn)導(dǎo)師信息存在錯誤或者偏差，歡迎隨時與我們聯(lián)系，以便進行更新完善。 聯(lián)系方式